Results 231 to 240 of about 607,319 (267)

Pathophysiology of chronic heart failure

The American Journal of Medicine, 2001
Heart failure is a changing paradigm. The hemodynamic model, which served our needs well from the 1950s through the early 1980s, has now been largely abandoned, except for the management of decompensated patients in the hospital. The pathophysiology is exceedingly complex and involves structural changes, such as loss of myofilaments, apoptosis and ...
openaire   +2 more sources

Bisoprolol in chronic heart failure

Hospital Medicine, 2000
The evidence for the use of beta-blockers in heart failure is substantial. Latest recommendations and guidelines suggest that most heart failure patients should be on a drug regimen of an angiotensin-converting enzyme inhibitor, diuretic and a beta-blocker.
openaire   +2 more sources

Homocysteine in Chronic Heart Failure

Clinical Laboratory, 2015
Hyperhomocysteinemia (HHcy) is a risk factor for cardiovascular disease. Homocysteine (Hcy) can generate reactive oxygen species. Oxidative stress enhances the progression of cardiovascular diseases and has long been implicated in chronic heart failure (CHF).
Pauline, Fournier, Joelle, Fourcade, Jérome, Roncalli, Robert, Salvayre, Michel, Galinier, Elizabeth, Caussé   +5 more
openaire   +2 more sources

[Anemia in chronic heart failure].

Revista clinica espanola, 2011
Anemia is one of the most common comorbidities in patients with decompensated chronic heart failure admitted to the Internal Medicine Ward. However, although there is evidence supporting its treatment to improve the functional capacity of the patients and to reduce the new admissions rate, the clinical practice guidelines do not provide any directives ...
Grau-Amoros, J, Formiga, F, Urrutia, A
openaire   +2 more sources

Management of chronic heart failure

Drugs of Today, 1999
Although chronic heart failure remains a major source of morbidity and mortality, recent advances in treatment have resulted in substantial improvements in survival, quality of life and exercise capacity, while at the same time reducing hospitalizations and overall cost of care.
openaire   +2 more sources

Drugs for Chronic Heart Failure

The Medical Letter on Drugs and Therapeutics
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient’s left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure ...
openaire   +2 more sources

Microparticles in Chronic Heart Failure

2017
Heart failure (HF) continues to have a sufficient impact on morbidity, mortality, and disability in developed countries. Growing evidence supports the hypothesis that microparticles (MPs) might contribute to the pathogenesis of the HF development playing a pivotal role in the regulation of the endogenous repair system, thrombosis, coagulation ...
openaire   +2 more sources

The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure

New England Journal of Medicine, 1996
Milton Packer, Jay N Cohn, Michael B Fowler   +2 more
exaly  

A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure

New England Journal of Medicine, 1991
Gary Johnson, Gary Francis, Maylene Wong   +2 more
exaly  

Cardiac Resynchronization in Chronic Heart Failure

New England Journal of Medicine, 2002
Andrew L Smith, David B Delurgio, Angel R Leon   +2 more
exaly